Early liver transplantation for severe alcoholic hepatitis
Jonathan Nahas, Gene Y. Im – 6 April 2018
Jonathan Nahas, Gene Y. Im – 6 April 2018
Samarth S. Patel, Mohammad Shadab Siddiqui – 6 April 2018
Tram T. Tran – 6 April 2018
Jorge A. Marrero, Laura M. Kulik, Claude B. Sirlin, Andrew X. Zhu, Richard S. Finn, Michael M. Abecassis, Lewis R. Roberts, Julie K. Heimbach – 6 April 2018
Nazia Selzner, Marina Berenguer – 6 April 2018 – Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high‐quality liver grafts are much needed. Direct‐acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV‐positive donors into HCV‐negative recipients.
Nancy Reau – 6 April 2018
Jason Lewis – 6 April 2018
Jason Lewis – 6 April 2018
Justine Hum, Janice H. Jou – 6 April 2018
Samarth S. Patel, Luis A. Guzman, Fei‐Pi Lin, Taylor Pence, Trevor Reichman, Binu John, Francesco S. Celi, Erika Liptrap, Chandra Bhati, Mohammad S. Siddiqui – 6 April 2018 – Coronary artery disease (CAD) assessment is a vital part of liver transplantation (LT) evaluation, as it allows for identification and medical optimization prior to transplantation. Although aspirin and statins are standard of care for CAD, they are not universally used in cirrhosis due to concerns about adverse events.